Vemurafenib (Norwegian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Vemurafenib" in Norwegian language version.
refsWebsite
Global rank
Norwegian rank
1st place
1st place
5,225th place
9,018th place
low place
low place
low place
low place
6th place
42nd place
7th place
33rd place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
low place
archive.org
- Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (juli 2012). «Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion». Nature. 487 (7408): 500–4. PMID 22763439. doi:10.1038/nature11183.
asco.org
- Flaherty K. «Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer». 2009 ASCO Annual Meeting Abstract, J Clin Oncol 27:15s, 2009 (suppl; abstr 9000). Arkivert fra originalen . Besøkt 26. desember 2015. «Arkivert kopi». Arkivert fra originalen 27. januar 2013. Besøkt 26. desember 2015.
bbc.co.uk
news.bbc.co.uk
- «Drug hope for advanced melanoma». BBC News. 2. juni 2009. Besøkt 7. juni 2009.
cancertherapyadvisor.com
clinicaltrials.gov
- «Safety Study of PLX4032 in Patients With Solid Tumors». ClinicalTrials.gov.
- «A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma». ClinicalTrials.gov. 15. februar 2010.
doi.org
- Mal:PDB; «Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma». Nature. 467 (7315): 596–599. September 2010. PMC 2948082
. PMID 20823850. doi:10.1038/nature09454. - Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P (November 2012). «Vemurafenib: the first drug approved for BRAF-mutant cancer». Nat Rev Drug Discov. 11 (11): 873–86. PMID 23060265. doi:10.1038/nrd3847.
- Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C (mai 2008). «BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells». Mol. Cancer Res. 6 (5): 751–9. PMID 18458053. doi:10.1158/1541-7786.MCR-07-2001.
- Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (2015). «Metastatic melanoma - a review of current and future treatment options». Acta Derm Venereol. 95 (5): 516-524. PMID 25520039. doi:10.2340/00015555-2035.
- Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S (februar 2010). «RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth». Nature. 464 (7287): 431–5. PMID 20130576. doi:10.1038/nature08833.
- Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M (februar 2010). «PLX4032, a Selective BRAF(V600E) Kinase Inhibitor, Activates the ERK Pathway and Enhances Cell Migration and Proliferation of BRAF(WT) Melanoma Cells». Pigment Cell Melanoma Res. 23 (2): 190–200. PMC 2848976 . PMID 20149136. doi:10.1111/j.1755-148X.2010.00685.x.
- Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (November 2010). «Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation». Nature. 468 (7326): 973–977. PMC 3143360 . PMID 21107323. doi:10.1038/nature09626.
- Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (juli 2012). «Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion». Nature. 487 (7408): 500–4. PMID 22763439. doi:10.1038/nature11183.
- Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. (juli 2012). «Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.». Nature. 487 (7408): 505–9. PMID 22763448. doi:10.1038/nature11249.
- Garber K (desember 2009). «Melanoma drug vindicates targeted approach». Science. 326 (5960): 1619. PMID 20019269. doi:10.1126/science.326.5960.1619.
- Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (August 2010). «Inhibition of mutated, activated BRAF in metastatic melanoma». N. Engl. J. Med. 363 (9): 809–19. PMID 20818844. doi:10.1056/NEJMoa1002011.
exelixis.com
- Cobimetinib at exelixis.com Arkivert 4. februar 2015 hos Wayback Machine.
gene.com
- «FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer» (pressemelding). Genentech. Besøkt 17. august 2011.
genengnews.com
hc-sc.gc.ca
- Notice of Decision for ZELBORAF Arkivert 2. mai 2012 hos Wayback Machine.
nih.gov
ncbi.nlm.nih.gov
- Mal:PDB; «Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma». Nature. 467 (7315): 596–599. September 2010. PMC 2948082 . PMID 20823850. doi:10.1038/nature09454.
- Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P (November 2012). «Vemurafenib: the first drug approved for BRAF-mutant cancer». Nat Rev Drug Discov. 11 (11): 873–86. PMID 23060265. doi:10.1038/nrd3847.
- Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C (mai 2008). «BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells». Mol. Cancer Res. 6 (5): 751–9. PMID 18458053. doi:10.1158/1541-7786.MCR-07-2001.
- Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F (2015). «Metastatic melanoma - a review of current and future treatment options». Acta Derm Venereol. 95 (5): 516-524. PMID 25520039. doi:10.2340/00015555-2035.
- Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S (februar 2010). «RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth». Nature. 464 (7287): 431–5. PMID 20130576. doi:10.1038/nature08833.
- Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M (februar 2010). «PLX4032, a Selective BRAF(V600E) Kinase Inhibitor, Activates the ERK Pathway and Enhances Cell Migration and Proliferation of BRAF(WT) Melanoma Cells». Pigment Cell Melanoma Res. 23 (2): 190–200. PMC 2848976 . PMID 20149136. doi:10.1111/j.1755-148X.2010.00685.x.
- Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (November 2010). «Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation». Nature. 468 (7326): 973–977. PMC 3143360 . PMID 21107323. doi:10.1038/nature09626.
- Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (juli 2012). «Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion». Nature. 487 (7408): 500–4. PMID 22763439. doi:10.1038/nature11183.
- Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. (juli 2012). «Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.». Nature. 487 (7408): 505–9. PMID 22763448. doi:10.1038/nature11249.
- Garber K (desember 2009). «Melanoma drug vindicates targeted approach». Science. 326 (5960): 1619. PMID 20019269. doi:10.1126/science.326.5960.1619.
- Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (August 2010). «Inhibition of mutated, activated BRAF in metastatic melanoma». N. Engl. J. Med. 363 (9): 809–19. PMID 20818844. doi:10.1056/NEJMoa1002011.
nytimes.com
- Harmon, Amy (21. februar 2010). «A Roller Coaster Chase for a Cure». The New York Times.
onclive.com
- «BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma». Oncology & Biotech News. 5 (7). juli 2011. Arkivert fra originalen 31. juli 2018. Besøkt 26. desember 2015.
oncotherapynetwork.com
- «MEK/BRAF Inhibitor Combo Reduces Death by One-Third in Melanoma». 2015. Arkivert fra originalen . Besøkt 26. desember 2015. «Arkivert kopi». Arkivert fra originalen 27. desember 2015. Besøkt 26. desember 2015.
oncozine.com
- Hofland P (20. februar 2012). «First Personalized Cancer Medicine Allows Patients with Deadly Form of Metastatic Melanoma to Live Significantly Longer». Onco'Zine. The International Cancer Network. Arkivert fra originalen 11. april 2012. «Arkivert kopi». Arkivert fra originalen 11. april 2012. Besøkt 26. desember 2015.
plexxikon.com
- «Plexxikon Announces First Patient Dosed in Phase 3 Trial of PLX4032 (RG7204) for Metastatic Melanoma» (pressemelding). Plexxiko. 8. januar 2010. Arkivert fra originalen 1. desember 2020. Besøkt 26. desember 2015.
web.archive.org
- Notice of Decision for ZELBORAF Arkivert 2. mai 2012 hos Wayback Machine.
- Hofland P (20. februar 2012). «First Personalized Cancer Medicine Allows Patients with Deadly Form of Metastatic Melanoma to Live Significantly Longer». Onco'Zine. The International Cancer Network. Arkivert fra originalen 11. april 2012. «Arkivert kopi». Arkivert fra originalen 11. april 2012. Besøkt 26. desember 2015.
- Flaherty K. «Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer». 2009 ASCO Annual Meeting Abstract, J Clin Oncol 27:15s, 2009 (suppl; abstr 9000). Arkivert fra originalen . Besøkt 26. desember 2015. «Arkivert kopi». Arkivert fra originalen 27. januar 2013. Besøkt 26. desember 2015.
- «Plexxikon Announces First Patient Dosed in Phase 3 Trial of PLX4032 (RG7204) for Metastatic Melanoma» (pressemelding). Plexxiko. 8. januar 2010. Arkivert fra originalen 1. desember 2020. Besøkt 26. desember 2015.
- Cobimetinib at exelixis.com Arkivert 4. februar 2015 hos Wayback Machine.
- «MEK/BRAF Inhibitor Combo Reduces Death by One-Third in Melanoma». 2015. Arkivert fra originalen . Besøkt 26. desember 2015. «Arkivert kopi». Arkivert fra originalen 27. desember 2015. Besøkt 26. desember 2015.
- «BRIM-2 Upholds Benefits Emerging with Vemurafenib in Melanoma». Oncology & Biotech News. 5 (7). juli 2011. Arkivert fra originalen 31. juli 2018. Besøkt 26. desember 2015.